A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Bemarituzumab Monotherapy and Combination With Other Anti-Cancer Therapy in Subjects With Squamous-Cell Non-Small-Cell Lung Cancer (FORTITUDE-201)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 30 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antineoplastics (Primary) ; Bemarituzumab (Primary) ; Carboplatin (Primary) ; Docetaxel (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions
Acronyms FORTITUDE-201
Sponsors Amgen

Most Recent Events

26 Oct 2024 Status changed from completed to discontinued. (Business decision not due to safety concerns.)
18 Jun 2024 Status changed from active, no longer recruiting to completed.
08 May 2024 Planned End Date changed from 30 Apr 2024 to 31 May 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight